Bicara Therapeutics Inc. BCAX
10.07 USD -0.46 (-4.42%)
Nov 12, 2026, 1:19 PM EST
9.97 Day range 10.45
7.87 52-week range 30.99
- YTD
- -40.20%
- 1 year
- -32.49%
Benzinga news
benzinga.com HC Wainwright & Co. Maintains Buy on Bicara Therapeutics, Lowers Price Target to $36 HC Wainwright & Co. analyst Robert Burns maintains Bicara Therapeutics (NASDAQ:BCAX) with a Buy and lowers the price target from $42 to $36.
benzinga.com Morgan Stanley Maintains Overweight on Bicara Therapeutics, Lowers Price Target to $30 Morgan Stanley analyst Judah Frommer maintains Bicara Therapeutics (NASDAQ:BCAX) with a Overweight and lowers the price target from $41 to $30.
benzinga.com Stifel Maintains Buy on Bicara Therapeutics, Lowers Price Target to $43 Stifel analyst Stephen Willey maintains Bicara Therapeutics (NASDAQ:BCAX) with a Buy and lowers the price target from $45 to $43.
benzinga.com BTIG Maintains Buy on Bicara Therapeutics, Lowers Price Target to $37 BTIG analyst Jeet Mukherjee maintains Bicara Therapeutics (NASDAQ:BCAX) with a Buy and lowers the price target from $39 to $37.
benzinga.com Bicara Therapeutics Q3 2026 Earnings Call Transcript Bicara Therapeutics (NASDAQ:BCAX) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…- benzinga.com Bicara Therapeutics Q3 EPS $(1.04) Misses $(0.81) Estimate Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(1.04) per share which missed the analyst consensus estimate of $(0.81) by 28.4 percent. This is a 55.22 percent decrease over losses…
benzinga.com Fabrinet, EverQuote, Lattice Semiconductor, Fiserv And Other Big Stocks Moving Higher On Tuesday U.S. stocks mixed as Dow fell 200 points; Fabrinet surged 13.7% on strong results, guidance and buyback, while several small caps rallied.- benzinga.com Goldman Sachs Downgrades Bicara Therapeutics to Sell, Lowers Price Target to $8 Goldman Sachs analyst Richard Law downgrades Bicara Therapeutics (NASDAQ:BCAX) from Neutral to Sell and lowers the price target from $20 to $8.
- benzinga.com Wedbush Maintains Outperform on Bicara Therapeutics, Lowers Price Target to $24 Wedbush analyst David Nierengarten maintains Bicara Therapeutics (NASDAQ:BCAX) with a Outperform and lowers the price target from $33 to $24.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Pulmonx (NASDAQ:LUNG) stock increased by 33.1% to $2.63 during Wednesday's regular session. The company's market cap stands at $85.0 million. As per the press release, Q3 earnings came out…
benzinga.com BTIG Reiterates Buy on Bicara Therapeutics, Maintains $39 Price Target BTIG analyst Jeet Mukherjee reiterates Bicara Therapeutics (NASDAQ:BCAX) with a Buy and maintains $39 price target.
benzinga.com BMO Capital Initiates Coverage On Bicara Therapeutics with Outperform Rating, Announces Price Target of $35 BMO Capital analyst David Lebowitz initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Outperform rating and announces Price Target of $35.- benzinga.com Goldman Sachs Maintains Neutral on Bicara Therapeutics, Raises Price Target to $20 Goldman Sachs analyst Richard Law maintains Bicara Therapeutics (NASDAQ:BCAX) with a Neutral and raises the price target from $18 to $20.
benzinga.com Wedbush Maintains Outperform on Bicara Therapeutics, Raises Price Target to $33 Wedbush analyst David Nierengarten maintains Bicara Therapeutics (NASDAQ:BCAX) with a Outperform and raises the price target from $30 to $33.- benzinga.com Morgan Stanley Maintains Overweight on Bicara Therapeutics, Raises Price Target to $39 Morgan Stanley analyst Judah Frommer maintains Bicara Therapeutics (NASDAQ:BCAX) with a Overweight and raises the price target from $37 to $39.
- benzinga.com Mizuho Maintains Neutral on Bicara Therapeutics, Raises Price Target to $20 Mizuho analyst Joseph Catanzaro maintains Bicara Therapeutics (NASDAQ:BCAX) with a Neutral and raises the price target from $18 to $20.
benzinga.com Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results Bicara Therapeutics (BCAX) reported a narrower-than-expected loss in Q2. Analysts raised price targets, but shares dipped 14.3% to $23.76. #BCAX #earnings- benzinga.com Wells Fargo Maintains Equal-Weight on Bicara Therapeutics, Raises Price Target to $23 Wells Fargo analyst Eva Fortea Verdejo maintains Bicara Therapeutics (NASDAQ:BCAX) with a Equal-Weight and raises the price target from $16 to $23.
- benzinga.com BTIG Maintains Buy on Bicara Therapeutics, Raises Price Target to $39 BTIG analyst Jeet Mukherjee maintains Bicara Therapeutics (NASDAQ:BCAX) with a Buy and raises the price target from $28 to $39.
- benzinga.com Bicara Therapeutics Q2 EPS $(0.82) Beats $(0.84) Estimate Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.82) per share which beat the analyst consensus estimate of $(0.84) by 2.38 percent. This is a 64 percent decrease over losses of…
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock increased by 91.1% to $6.04 during Friday's after-market session. The company's market cap stands at $2.2 million. BGM Group (NASDAQ:BGM) stock…
benzinga.com Bicara Therapeutics' Ficerafusp Alfa Plus Pembrolizumab Shows 31% Estimated 3-Year Overall Survival And Durable Responses In First-Line HPV-Negative Head And Neck Cancer Phase 1b Study At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a
benzinga.com Goldman Sachs Maintains Neutral on Bicara Therapeutics, Raises Price Target to $18 Goldman Sachs analyst Richard Law maintains Bicara Therapeutics (NASDAQ:BCAX) with a Neutral and raises the price target from $16 to $18.- benzinga.com Morgan Stanley Maintains Overweight on Bicara Therapeutics, Raises Price Target to $37 Morgan Stanley analyst Judah Frommer maintains Bicara Therapeutics (NASDAQ:BCAX) with a Overweight and raises the price target from $36 to $37.
- benzinga.com Guggenheim Initiates Coverage On Bicara Therapeutics with Buy Rating, Announces Price Target of $42 Guggenheim analyst Brad Canino initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Buy rating and announces Price Target of $42.
- benzinga.com Bicara Therapeutics Q1 EPS $(0.93) Misses $(0.68) Estimate Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.93) per share which missed the analyst consensus estimate of $(0.68) by 36.76 percent. This is a 36.76 percent decrease over losses…
benzinga.com Earnings Scheduled For May 11, 2026 
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session - benzinga.com Goldman Sachs Maintains Neutral on Bicara Therapeutics, Raises Price Target to $16 Goldman Sachs analyst Richard Law maintains Bicara Therapeutics (NASDAQ:BCAX) with a Neutral and raises the price target from $14 to $16.
- benzinga.com Wedbush Reiterates Outperform on Bicara Therapeutics, Maintains $30 Price Target Wedbush analyst David Nierengarten reiterates Bicara Therapeutics (NASDAQ:BCAX) with a Outperform and maintains $30 price target.
- benzinga.com Wells Fargo Maintains Equal-Weight on Bicara Therapeutics, Raises Price Target to $16 Wells Fargo analyst Eva Fortea Verdejo maintains Bicara Therapeutics (NASDAQ:BCAX) with a Equal-Weight and raises the price target from $11 to $16.
benzinga.com Bicara Therapeutics To Rally Around 121%? Here Are 10 Top Analyst Forecasts For Tuesday Top analysts changed outlook on top names. See all changes on analyst ratings page. BTIG & HCW cut price targets, Needham & BMO raised, Baird bcut.- benzinga.com Citizens Reiterates Market Outperform on Bicara Therapeutics, Maintains $31 Price Target Citizens analyst Reni J. Benjamin reiterates Bicara Therapeutics (NASDAQ:BCAX) with a Market Outperform and maintains $31 price target.
- benzinga.com HC Wainwright & Co. Maintains Buy on Bicara Therapeutics, Raises Price Target to $42 HC Wainwright & Co. analyst Robert Burns maintains Bicara Therapeutics (NASDAQ:BCAX) with a Buy and raises the price target from $40 to $42.
- benzinga.com Bicara Therapeutics Q4 EPS $(0.68), Inline Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.68) per share which met the analyst consensus estimate. This is a 74.36 percent decrease over losses of $(0.39) per share from the…
- benzinga.com Earnings Scheduled For March 30, 2026
benzinga.com Bicara Therapeutics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call Bicara Therapeutics Inc (BCAX) to release Q4 earnings on March 30. Expected loss of 65 cents/share. Analysts have mixed ratings and price targets.- benzinga.com B of A Securities Initiates Coverage On Bicara Therapeutics with Buy Rating, Announces Price Target of $35 B of A Securities analyst Tazeen Ahmad initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Buy rating and announces Price Target of $35.
- benzinga.com Bicara Therapeutics Data From Phase 1b Expansion Cohort Of 2000mg Of Ficerafusp Alfa Every Other Week In Combination With Pembrolizumab Shows Q2W Generally Well-Tolerated, Safety Profile Consistent; Demonstrated 48% Overall Response Rate Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today presented…
- benzinga.com Citizens Initiates Coverage On Bicara Therapeutics with Market Outperform Rating, Announces Price Target of $31 Citizens analyst Reni J. Benjamin initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Market Outperform rating and announces Price Target of $31.
- benzinga.com Wedbush Reiterates Outperform on Bicara Therapeutics, Maintains $30 Price Target Wedbush analyst David Nierengarten reiterates Bicara Therapeutics (NASDAQ:BCAX) with a Outperform and maintains $30 price target.
- benzinga.com Bicara Therapeutics Selects 1500 Mg Of Ficerafusp Alfa As Optimal Dose For Phase 3 Of FORTIFI-HN01 Pivotal Trial Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today provided a 2026…
- benzinga.com BTIG Initiates Coverage On Bicara Therapeutics with Buy Rating, Announces Price Target of $28 BTIG analyst Jeet Mukherjee initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Buy rating and announces Price Target of $28.
- benzinga.com Mizuho Initiates Coverage On Bicara Therapeutics with Neutral Rating, Announces Price Target of $18 Mizuho analyst Joseph Catanzaro initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Neutral rating and announces Price Target of $18.
- benzinga.com Reported Saturday, Bicara Therapeutics Reports 57% Confirmed Overall Response Rate With 750mg Ficerafusp Alfa Weekly Plus Pembrolizumab, Supporting Pivotal Interim Analysis Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety profile comparable to 1500mg QW dose, further derisking pivotal FORTIFI-HN01 study…
- benzinga.com Bicara Therapeutics Shares Early Trial Results Backing FDA-Supported Fast-Track Drug Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the…
- benzinga.com Wells Fargo Maintains Equal-Weight on Bicara Therapeutics, Raises Price Target to $11 Wells Fargo analyst Eva Fortea Verdejo maintains Bicara Therapeutics (NASDAQ:BCAX) with a Equal-Weight and raises the price target from $8 to $11.
- benzinga.com Bicara Therapeutics Q3 EPS $(0.67) Misses $(0.54) Estimate Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.67) per share which missed the analyst consensus estimate of $(0.54) by 23.84 percent. This is a 58.13 percent increase over losses…
benzinga.com 4 Biotech Stocks Seeing Explosive Momentum Gains The SPDR S&P Biotech ETF (ARCA:XBI) is up more than 40% over the past six months and is on the verge of breaking out. Here's a look at several momentum standouts in the biotech space that appear to…- benzinga.com Bicara Therapeutics Files For Mixed Shelf Offering Of Up To $400M https://www.sec.gov/Archives/edgar/data/2023658/000119312525230307/d54249ds3.htm